DOCSLIB.ORG

T Cells the Usual Subsets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
T Cells the Usual Subsets T cells: the usual subsets Chen Dong and Gustavo J. Martinez T cells have important roles in immune responses and function by directly secreting soluble mediators or important for adaptation of immune responses in different microenvironments and might be particularly through cell contact-dependent mechanisms. Many T cell subsets have been characterized. Although relevant for host defence against pathogens that colonize different tissues. Distinct T cell subsets, or effector T cells were originally considered to be terminally differentiated, a growing body of evidence has differentiation states, can be identified based on the cell surface markers expressed and/or the effector challenged this view and suggested that the phenotype of effector T cells is not completely fixed but is molecules produced by a particular T cell population. This Poster summarizes our current understanding of more flexible or plastic. T cells can have ‘mixed’ phenotypes (that is, have characteristics usually the surface markers, transcriptional regulators, effector molecules and functions of the different T cell associated with more than one T cell subset) and can interconvert from one subset phenotype to another, subsets that participate in immune responses. Further knowledge of how these T cell subsets are regulated IMMUNOLOGY although instructive signalling can lead to long-term fixation of cytokine memory. T cell plasticity can be and cooperate with each other will provide us with better tools to treat immune-related diseases. Cytotoxic T cell Exhausted T cell Anergic T cell TR1 cell Natural TReg cell NKT cell CD8αα T cell Surface αβ TCR, CD3, CD8 Surface CD3, CD8, PD1, Surface αβ TCR, CD3, BTLA Surface αβ TCR, CD3, CD4 Surface phenotype αβ TCR, CD3, CD4, CD25, CTLA4, GITR Surface phenotype NK1.1, SLAMF1, SLAMF6, TGFβR, Surface αβ or γδ TCR, CD3, phenotype phenotype TIM3, 1B11, LAG3 phenotype phenotype Transcription factors FOXP3, STAT5, FOXO1, FOXO3 Vα14, Jα18 (mouse) phenotype CD8αα, B220 Transcription EOMES, T-bet, BLIMP1 Transcription BLIMP1 Effector GRAIL, CBL-B, ITCH, NEDD4 Vα24, Jα18 (human) Effector IL-10, TGF Transcription Not known Effector molecules secreted IL-10, TGFβ, IL-35 β factors factors factors factors Transcription PLZF molecules Function Mediate immunosuppression and tolerogenic responses factors secreted Effector Perforin, granzyme, IFNγ Function Generated in response Function These cells are generated Effector IL-10 through contact-dependent and -independent molecules to chronic antigen- following TCR activation in molecules mechanisms. These cells are generated in the thymus. Effector molecules IL-4, IFNγ, IL-17A Function Intraepithelial lymphocytes secreted mediated TCR the absence of co-stimulatory secreted secreted are found in the gut. They can stimulation. These signals, which leads them develop intra- or extra- Function Cytotoxic; kill infected and Function Immunosuppression Function Can have both pro- and anti-inflammatory cells express inhibitory to become unresponsive to Inducible TReg cell thymically. They express or transformed cells and thereby mediated by IL-10 functions. Have been shown to modulate immune αβ receptors and lack subsequent stimulatory signals. Surface phenotype αβ TCR, CD3, CD4, CD25, CTLA4, GITR TCRs. TCR+ cells express protect the host from viral production. These cells responses in several different settings, including γδ γδ effector cytokine They are functionally inactive KGF, whereas TCR+ cells do infections and cancer. Direct are generated from naive Transcription factors FOXP3, FOXO1, FOXO3, STAT5, SMAD2, SMAD3, SMAD4 cancer, autoimmunity, allergy, infection and graft- αβ production; they cells and fail to proliferate or not. Most TCRs are killing is mediated by secretion of T cells in the presence of Effector molecules secreted IL-10, TGF versus-host disease. αβ therefore fail to mount produce IL-2. Their generation β enriched for self-reactivity. perforin and granzymes, which TGF and IL-27 or in the Other features SAP expression. CD1-restricted TCR. effective antiviral may be important for avoiding β Function Promote immunosuppression and tolerance by They require microglobulin- cause apoptosis of target cells. presence of the immuno- MAIT cells express an invariant TCR -chain β2 immune responses. autoimmune responses. contact-dependent and -independent mechanisms. α dependent MHC class I Other In humans, mainly CD45RO+. Some suppressive drugs (V 33J 19 in mice; V 7.2J 19 in humans). These cells are generated from naive T cells in the α α α α expression for their generation features terminally differentiated CTLs in Other Increased expression of p27KIP1, vitamin D3 and MAIT cells are MR1 restricted (not CD1 restricted) periphery and, at least in some cases, TGFβ and IL-2 and/or homeostasis. They can humans re-express CD45RA. features which leads to cell cycle arrest. dexamethasone. but have similarities to NKT cells. are important for their differentiation. have regulatory functions through the production of IL-10 and TGFβ. CD4 10’0µm TCR CD8 CD4 TCR TCR SLAMF1 TCR γδ TCR CD3 Cytokine CTLA4 SLAMF6 CD8αα TCR receptor CD3 Chemokine GITR CD3 TCR NK1.1 TGFβR TCR CD8 PD1 TIM3 1B11 CD3 8’0µm BTLA receptor CD25 IL-7R B220 TCR CD62L LAG3 CD44 CD3 CD3 CD3 CD3 IL-7R CD3 CCR7 6’0µm CCR7 4’0µm Naive Cytotoxic Exhausted Anergic Helper Regulatory Memory NKT γδ CD8αα + CD4 αβ T cell TH1 cell TH17 cell Central memory T cell γδ T cell Surface phenotype αβ TCR, CD3, CD4, CCR7, CD62Lhi, IL-7R (CD127) Surface phenotype αβ TCR, CD3, CD4, IL-12R, IFNγR, CXCR3 Surface phenotype αβ TCR, CD3, CD4, IL-23R, CCR6, IL-1R, Surface phenotype CCR7hi, CD44, CD62Lhi, TCR, CD3, Surface γδ TCR, CD3 phenotype Transcription THPOK Transcription factors T-bet, STAT4, STAT1 CD161 (human only) IL-7R (CD127), IL-15R Effector IFN , IL-17A, IL-17F, IL-22 factors Effector molecules secreted IFN , IL-2, LT Transcription factors RORγt, STAT3, RORα Transcription factors BCL-6, BCL-6B, MBD2, BMI1 γ γ α molecules Function Patrol through lymph nodes scanning peptide– Effector molecules secreted IL-17A, IL-17F, IL-21, IL-22, CCL20 Effector molecules IL-2, CD40L Function Promote protective immunity against intracellular pathogens. By secreting secreted MHC class II molecule complexes on APCs for IFN , they induce activation of macrophages and upregulation of iNOS, Function Promote protective immunity against extracellular bacteria and fungi, secreted Low levels IL-4, IFNγ, IL-17A γ Function Enriched at epithelial surfaces the presence of their cognate antigen. Following leading to the killing of intracellular pathogens such as Leishmania major, mainly at mucosal surfaces. Also promote autoimmune and inflammatory Function Preferentially reside in secondary lymphoid + and can have both pro- and activation by APCs, naive CD4 T cells Listeria monocytogenes and Mycobacterium spp. Their development is diseases. Generated in the presence of TGF and IL-6 and/or IL-21 and are organs, mounting recall responses to β anti-inflammatory functions, differentiate into effector or regulatory T cells; regulated by IL-12. maintained by IL-23 and IL-1. antigens. Even though these cells lack activated naive T cells also give rise to memory immediate effector functions, they rapidly depending on the γδ TCR Other features Also express BATF, IκBζ, IRF4 and AHR transcription factors. Human T 17 cells T cells. H proliferate and differentiate into effector and the context. Have T 2 cell also produce IL-26. characteristics of both innate Other features CD45RA expressed by human cells. H T cells following antigen stimulation. Surface phenotype αβ TCR, CD3, CD4, IL-4R, IL-33R, CCR4, IL-17RB, CRTH2 and adaptive immunity. TH22 cell Other CD8+ αβ T cell Transcription factors GATA3, STAT6, DEC2, MAF Effector memory T cell IFNγ- and IL-17A-producing Surface phenotype αβ TCR, CD3, CD4, CCR10 low features cells are distinct populations hi Effector molecules secreted IL-4, IL-5, IL-13, IL-10 Surface phenotype CD62L , CD44, TCR, CD3, IL-7R (CD127), Surface phenotype αβ TCR, CD3, CD8, CCR7, CD62L , IL-7R (CD127) that can be distinguished by Transcription factors AHR IL-15R, CCR7low Transcription RUNX3 Function Promote humoral immune responses and host defence against extracellular CD27 and CCR6 expression. Effector molecules secreted IL-22 factors parasites. However, they can also potentiate allergic responses and asthma. Transcription factors BLIMP1 Innate immune recognition by Their development and maintenance is regulated by IL-4, IL-25 and IL-33. Function Identified in inflammatory skin diseases. Their role in host defence remains Function Patrol through lymph nodes scanning peptide– Effector molecules Rapid and high production of inflammatory expression of TLRs. unclear as this subset has only recently been characterized. Their identity as an MHC class I molecule complexes for the Other features IRF4 is also an important transcription factor. secreted cytokines independent T cell subset needs to be confirmed. presence of their cognate antigen. Following H Function Preferentially found in peripheral tissues. activation by APCs, they differentiate into T 9 cell They provide immediate protection upon H T cell CTLs and memory T cells. Surface phenotype αβ TCR, CD3, CD4 FH antigen challenge through, for example, the Surface phenotype TCR, CD3, CD4, CXCR5, SLAM, OX40L, CD40L, ICOS, IL-21R, PD1 rapid production of effector cytokines. Other features CD45RA expressed by human cells. Transcription factors PU.1 αβ Transcription factors BCL-6, STAT3 Effector molecules secreted IL-9,
Load more

Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • T Lymphocytes + and CD8 +CD4 TCR/CD3 Complex in Immortalized Mature -Deficient Γ Signaling Through A
    Signaling Through a CD3γ-Deficient TCR/CD3 Complex in Immortalized Mature CD4+ and CD8+ T Lymphocytes This information is current as Alberto Pacheco-Castro, David Alvarez-Zapata, Pilar of September 25, 2021. Serrano-Torres and José R. Regueiro J Immunol 1998; 161:3152-3160; ; http://www.jimmunol.org/content/161/6/3152 Downloaded from References This article cites 47 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/161/6/3152.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1998 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Signaling Through a CD3g-Deficient TCR/CD3 Complex in Immortalized Mature CD41 and CD81 T Lymphocytes1 Alberto Pacheco-Castro,2 David Alvarez-Zapata,2 Pilar Serrano-Torres, and Jose´R. Regueiro3 The biologic role of each CD3 chain and their relative contribution to the signals transduced through the TCR/CD3 complex and to downstream activation events are still controversial: they may be specialized or redundant.
    [Show full text]
  • 18F-Farag PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy
    Journal of Nuclear Medicine, published on November 6, 2020 as doi:10.2967/jnumed.120.249078 18F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy Jelena Levi1*, Samuel Goth1, Lyna Huynh1, Tina Lam1, Tony L Huynh2, Brailee Schulte2, Juliet A Packiasamy1 1CellSight Technologies Incorporated, San Francisco, California; 2Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; *Corresponding Author Jelena Levi, PhD 185 Berry street, San Francisco, 94107, CA Email: [email protected] Running Title: [18F]F-AraG for CD8 profiling of tumors Financial statement: This work was supported by National Institutes of Health Grants NCI SBIR HHSN261201800024C (JL). Conflict of Interest Statement: JL, SG, LH, TL and JP are or were employed by CellSight Technologies. CellSight Technologies Incorporated is commercializing [18F]F-AraG as a PET tracer for evaluation of immune response in immunotherapy. No other potential conflicts of interest relevant to this article exist. ABSTRACT Majority of the clinical trials exploring various combinations of chemo- and immunotherapy rely on serial biopsy to provide information on immune response. The aim of this study was to assess the value of 18F-FAraG as a non-invasive tool that could profile tumors based on the key players in adaptive antitumor response, CD8+ cells, and evaluate immunomodulatory effects of chemotherapy. Methods. To evaluate the ability of 18F-FAraG to report on the presence of CD8+ cells within the TME, we imaged a panel of syngeneic tumor models (MC38, CT26, LLC, A9F1, 4T1 and B16F10), and correlated the signal intensity with the number of lymphocytes found in the tumors.
    [Show full text]
  • CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells With
    + CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells.
    [Show full text]
  • Identification of 18 Immune Cell Subsets Using 13-Color Panel
    Immunophenotyping Identification of 18 immune cell subsets in human blood using a 13-color panel Background Cell type Function Phenotype Flow cytometry has become the method of choice for Eosinophils Parasitic immunity CD45+, SSCmid/hi, CD14 –, CD16 –, CD19– immunophenotyping and identifying specific cellular + mid/hi subsets. Within seconds, it provides a thorough overview of Neutrophils Innate Immunity CD45 , SSC , CD14 –, CD16+, CD19– the major cell types that constitute a sample. Using multiple + mid markers simultaneously increases the number of parameters Classical Phagocytosis of CD45 , SSC , monocytes pathogens and CD14+, CD16– that can be analyzed per run and decreases the amount of antigen presentation starting material required to perform an assay. This can be Intermediate Phagocytosis of CD45+, SSCmid, critical for precious sample material and long-term immune- monocytes pathogens and CD14+, CD16mid monitoring studies. In this application note, we demonstrate antigen presentation 13-color immunophenotyping of human peripheral blood Non-classical Phagocytosis of CD45+, SSCmid, + + mononuclear cells (PBMCs) using the MACSQuant® Analyzer 16, monocytes pathogens and CD14 , CD16 antigen presentation a compact and reliable benchtop flow cytometer equipped + low + with three lasers. The markers selected allow for the Class-switched Adaptive immunity CD45 , SSC , CD19 , memory B cells CD27+, IgD–, CD14– simultaneous identification and analysis of 18 different cell Non-switched Adaptive immunity CD45+, SSClow, CD19+, populations, thus maximizing the amount of information that memory B cells CD27+, IgD+, CD14– can be retrieved from the sample material analyzed. This is Naive B cells Adaptive immunity – CD45+, SSClow, CD19+, critical when input material is limited, as is often the case for non-antigen CD27–, IgD+, CD14– pediatric or disease studies.
    [Show full text]
  • Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries with Limited Resources and for Triaging Cases Before
    AJCP /ORIGINAL ARTICLE Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries With Limited Resources and for Triaging Cases Before Referral to Specialist Centers Downloaded from https://academic.oup.com/ajcp/article-abstract/145/5/687/2195691 by World Health Organization user on 09 January 2019 Maria Giulia Disanto, MD,1 Maria Raffaella Ambrosio, MD, PhD,2 Bruno Jim Rocca, MD, PhD,2 Hazem A. H. Ibrahim, FRCPath, PhD,1,3 Lorenzo Leoncini, MD, PhD,2 and Kikkeri N. Naresh, MD, FRCPath1 From the 1Department of Histopathology, Imperial College Healthcare NHS Trust & Imperial College, London, United Kingdom; 2Department of Medical Biotechnologies, Section of Pathology, University of Siena, Siena, Italy; and 3Department of Histopathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Key Words: Lymphoma; B-cell lymphoma; Immunohistochemistry; Diagnosis; Classification; Developing countries Am J Clin Pathol May 2016;145:687-695 DOI: 10.1093/AJCP/AQW060 ABSTRACT Lymphomas are a collection of different malignancies “arising” from lymphoid cells. They include about 49 entities, Objectives: Establish and validate optimal minimal and over 19 provisional entities and subsets.1 About 85% of immunohistochemistry panels for usage in a staged lymphomas are of B-cell origin. Precision in lymphoma diag- algorithmic manner for precise diagnosis of B-cell nosis requires expertise and infrastructure. The entities are lymphomas in countries with limited resources. Suggest defined based on morphology, immunohistochemistry (on short panels of immunostains to be used in referring units some occasions in situ hybridization), cytogenetics/fluores- that refer suspected lymphomas to specialist diagnostic cent in situ hybridization (FISH), molecular genetics and clin- centers in resourceful countries.
    [Show full text]
  • Cd4/Cd8 Panel, Blood
    Lab Dept: Flow and Immunology Test Name: CD4/CD8 PANEL, BLOOD General Information Lab Order Codes: C48P Synonyms: Helper/Suppressor Ratio; T- cells; T-cell subsets; T-cell phenotyping See also: Immune Status Panel and Comprehensive Immune Status Panel CPT Codes: 86359 – T cells, total count 86360 – T cells; absolute CD4 and CD8 count, including ratio Test Includes: CD4(CD3+) and CD8(CD3+) relative percentages, absolute values and a calculated Helper/Suppressor ratio. Logistics Test Indications: This is a minimal antibody panel to monitor immune status. Lab Testing Sections: Flow Cytometry Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: 3 times weekly determined by volume. Transport collected specimen immediately to Flow Cytometry. Routine testing is not available on weekends or holidays. Therefore, specimens cannot be used if drawn the day before a 3 day weekend such as Memorial Day, Labor Day or major holiday that falls on a Monday or Friday. Turnaround Time: 1 – 3 days Special Instructions: See Test Availability Specimen Specimen Type: Whole blood Container: Lavender top (EDTA) tube Draw Volume: 2 mL blood in a 2 mL Lavender (EDTA) tube Minimum volume: 0.5 mL in an EDTA microtainer Collection: Routine venipuncture Special Processing: Keep sample at room temperature and forward promptly to the laboratory. Do not centrifuge, refrigerate, or freeze sample. Patient Preparation: None Sample Rejection: Specimens will not be processed that are clotted; hemolyzed; greater than 72 hours old; collected in the wrong tube type (0.5 mL in a 2 mL tube), or that have been held or handled at a temperature other than room temperature Interpretive Reference Range: Age-dependant reference ranges provided with results.
    [Show full text]
  • Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367
    Medicare Local Coverage Determination Policy Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367 CMS Policy for Alaska, Arizona, Idaho, Montana, North Dakota, Medically Supportive Oregon, South Dakota, Utah, Washington, and Wyoming ICD Codes are listed Local policies are determined by the performing test location. This is determined by the state on subsequent page(s) in which your performing laboratory resides and where your testing is commonly performed. of this document. Coverage Indications, Limitations, and/or Medical Necessity Flow cytometry (FCM) is a complex process to examine blood, body fluids, CSF, bone marrow, lymph node, tonsil, spleen and other solid tissues. The use of peripheral blood and fine needle aspirate material avoids more invasive procedures for diagnosis. A flow cytometer evaluates the physical and/or chemical characteristics of single cells as the cells pass individually in a fluid stream through a measuring device. Surface receptors, intracellular molecules, and DNA bind with fluorescent dyes that allow detection and evaluation. When light of one wave length excites electrons of certain chemicals to energy levels above their ground state and upon return to ground state emits light of a longer wavelength, fluorescence is produced. A flow cytometer detects cell characteristics by measuring the fluorescence produced by fluorochromes conjugated either directly with cell components or conjugated to antibodies directed against cell components. Indications • Cytopenias and Hypercellular Hematolymphoid Disorders Hematolymphoid neoplasia can present with cytopenias (anemia, leucopenia and/or thrombocytopenia) or elevated leukocyte counts. If medical review and preliminary laboratory testing fails to reveal a cause, bone marrow aspiration and biopsy are indicated to rule out an infiltrative process or a stem cell disorder.
    [Show full text]
  • MGD011, a CD19 X CD3 Dual-Affinity Retargeting Bi-Specific Molecule Incorporating Extended Circulating Half-Life for the Treatment of B-Cell Malignancies
    Published OnlineFirst September 23, 2016; DOI: 10.1158/1078-0432.CCR-16-0666 Cancer Therapy: Preclinical Clinical Cancer Research MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies Liqin Liu, Chia-Ying K. Lam, Vatana Long, Lusiana Widjaja, Yinhua Yang, Hua Li, Linda Jin, Steve Burke, Sergey Gorlatov, Jennifer Brown, Ralph Alderson, Margaret D. Lewis, Jeffrey L. Nordstrom, Scott Koenig, Paul A. Moore, Syd Johnson, and Ezio Bonvini Abstract Purpose: CD19, a B-cell lineage-specific marker, is highly autologous B-cell depletion in PBMCs from both species. represented in B-cell malignancies and an attractive target for MGD011-mediated killing was accompanied by target-depen- therapeutic interventions. MGD011 is a CD19 x CD3 DART dent T-cell activation and expansion, cytokine release and bispecific protein designed to redirect T lymphocytes to eliminate upregulation of perforin and granzyme B. MGD011 demon- CD19-expressing cells. MGD011 has been engineered with a strated antitumor activity against localized and disseminated modified human Fc domain for improved pharmacokinetic (PK) lymphoma xenografts reconstituted with human PBMCs. In properties and designed to cross-react with the corresponding cynomolgus monkeys, MGD011 displayed a terminal half-life antigens in cynomolgus monkeys. Here, we report on the preclin- of 6.7 days; once weekly intravenous infusion of MGD011 at ical activity, safety and PK properties of MGD011. dosesupto100mg/kg, the highest dose tested, was well Experimental Design: The activity of MGD011 was evaluated tolerated and resulted in dose-dependent, durable decreases in several in vitro and in vivo models.
    [Show full text]
  • CD3+CD5+CD4-CD8-) Alpha/Beta T Cell Receptor-Bearing Cells
    Mlsa generated suppressor cells. I. Suppression is mediated by double-negative (CD3+CD5+CD4-CD8-) alpha/beta T cell receptor-bearing cells. This information is current as of October 2, 2021. M Bruley-Rosset, I Miconnet, C Canon and O Halle-Pannenko J Immunol 1990; 145:4046-4052; ; http://www.jimmunol.org/content/145/12/4046 Downloaded from Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription by guest on October 2, 2021 Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1990 by American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. 0022-1767/90/14512-4046$02.00/0 THEJOURNAL OF IMMUNOLCGY Vol. 145.4046-4052. No. 12. December 15. 1990 Copyright 0 1990 by The American Association of lmmunologists Printed In U.S.A. Mls" GENERATED SUPPRESSORCELLS I. Suppression is Mediated by Double-Negative (CD3+CDVCD4-CD8-) a/@ T Cell Receptor-Bearing Cells' Grafting of cells from B10.D2 (H-2d)donors into H- The GVHR3 remains a major problem after bone mar- 2 compatible lethally irradiated (DBA/2 x B1O.DZ)Fl row transplantation, even in MHC-compatible donor-re- hostsresults in a severe graft-vs-host reaction cipient combinations.
    [Show full text]
  • Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature
    cells Article Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature 1, 2, 1, 1, Sónia Fonseca y, Vanessa Pereira y, Catarina Lau z, Maria dos Anjos Teixeira z, Marika Bini-Antunes 3 and Margarida Lima 1,* 1 Laboratory of Cytometry, Unit for Hematology Diagnosis, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), 4099-001 Porto Porto, Portugal; [email protected] (S.F.); [email protected] (C.L.); [email protected] (M.d.A.T.) 2 Department of Clinical Pathology, Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E), 4434-502 Vila Nova de Gaia, Portugal; [email protected] 3 Laboratory of Immunohematology and Blood Donors Unit, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), 4099-001Porto, Portugal; [email protected] * Correspondence: [email protected]; Tel.: + 351-22-20-77-500 These authors contributed equally to this work. y These authors contributed equally to this work. z Received: 10 February 2020; Accepted: 13 March 2020; Published: 16 March 2020 Abstract: Gamma delta T cells (Tc) are divided according to the type of Vδ and Vγ chains they express, with two major γδ Tc subsets being recognized in humans: Vδ2Vγ9 and Vδ1.
    [Show full text]
  • Ligand for Bovine CD5 the Identification and Characterization of A
    The Identification and Characterization of a Ligand for Bovine CD5 Karen M. Haas and D. Mark Estes This information is current as J Immunol 2001; 166:3158-3166; ; of September 27, 2021. doi: 10.4049/jimmunol.166.5.3158 http://www.jimmunol.org/content/166/5/3158 Downloaded from References This article cites 46 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/166/5/3158.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 27, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Identification and Characterization of a Ligand for Bovine CD51 Karen M. Haas* and D. Mark Estes2*† CD5, a type I glycoprotein expressed by T cells and a subset of B cells, is thought to play a significant role in modulating Ag receptor signaling. Previously, our laboratory has shown that bovine B cells are induced to express this key regulatory molecule upon Ag receptor cross-linking.
    [Show full text]